TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00081731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atacand/HCT, Caduet
Description: Atacand/HCT and caduet or optimal medical therapy for hypertension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Description: Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
Study: NCT03229148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conscious Sedation
Description: A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
Study: NCT00757185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl testosterone
Description: testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Study: NCT01617772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 1000mg L-carnitine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 1000mg L-carnitine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking placebo
Study: NCT00785213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone 4 mg Tablets
Description: Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg Tablets
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 324 mg Capsules
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
Study: NCT02582164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Biomedical Engineering's Long-working distance OCT
Description: The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
Study: NCT01917305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: platform-shifted implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platform-shifted implant
Study: NCT03871816

Intervention type: OTHER
Intervention: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
Description: Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
Study: NCT01071239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACs device
Description: Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Study: NCT04469673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological：JS002
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT01860742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alpha-2b
Description: Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATATE
Description: 177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
Study: NCT01902875

Intervention type: DRUG
Intervention: Paclitaxel + Cisplatin
Description: Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.

Intervention type: DRUG
Intervention: Paclitaxel + Cisplatin
Description: Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.

Intervention type: BIOLOGICAL
Intervention: CIK cell therapy
Description: Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
Study: NCT03840148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime/VNRX-5133 (taniborbactam)
Description: Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
Study: NCT00919906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My Scrivener(R)
Description: Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
Study: NCT03098056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROG2
Description: Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food
Study: NCT00691873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study: NCT03488849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureCRIC
Description: SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Freehand
Description: Freehand palpation approach to identification of the cricothyroid membrane
Study: NCT01152216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 20 mg orally three times daily
Study: NCT02690519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 1
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 2
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Study: NCT00551161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
Study: NCT02745691

Intervention type: OTHER
Intervention: Surgery
Description: Thoracic surgery for lung cancer

Intervention type: OTHER
Intervention: Radiochemotherapy
Description: Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)

Intervention type: OTHER
Intervention: Targeted therapy
Description: New targeted therapies for lung cancer

Intervention type: OTHER
Intervention: Immunotherapy
Description: New immunotherapies for lung cancer
Study: NCT02258334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine, 2014-2015 formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone I®ntradermal vaccine, 2014-2015 formulation
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine, 2014-2015 formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose vaccine, 2014-2015 formulation
Description: 0.5 mL, Intramuscular
Study: NCT02908074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules will be taken weekly for a maximum of 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules will be taken weekly for a maximum of 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGS649
Description: Capsules will be taken weekly for a maximum of 24 weeks
Study: NCT01314105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Study: NCT03437928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Deep Brain Stimulation
Description: Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
Study: NCT01872780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: single oral administration of 4mg of rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: single oral administration of 4mg of rosiglitazone

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C8 genotype
Description: CYP2C8\*11.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C8 genotype
Description: CYP2C8\*11.
Study: NCT01734850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Intravenous busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Intravenous busulfan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified HSPC
Description: Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified HSPC
Description: Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified HSPC
Description: Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified CD4+ T lymphocytes
Description: CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified CD4+ T lymphocytes
Description: CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cal-1 modified CD4+ T lymphocytes
Description: CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
Study: NCT02374190

Intervention type: OTHER
Intervention: Standard Hospital Care
Description: We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
Study: NCT05595330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymphedema prevention protocols
Description: Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room.
Study: NCT03885856

Intervention type: OTHER
Intervention: single row repair technique
Description: single row repair technique

Intervention type: OTHER
Intervention: double row repair technique
Description: double row repair technique
Study: NCT03728114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham RIC
Description: Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham RIC
Description: Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
Study: NCT02743793

Intervention type: PROCEDURE
Intervention: Blood Draw
Study: NCT03543722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National Career Coach Program
Description: Intensive employment services as described above.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local Community Resources Program
Description: Usual employment services as described above.
Study: NCT04503382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness Media
Description: As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kindness Media
Description: As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
Study: NCT04517370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional/Pixel CO2 laser
Description: The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fractional/Pixel CO2 laser
Description: The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation).
Study: NCT04048252

Intervention type: OTHER
Intervention: Focus group creation
Description: Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention

Intervention type: OTHER
Intervention: Workshop
Description: Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
Study: NCT04263090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
Study: NCT03876938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine 10 mg
Description: olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine 5 mg
Description: olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
Study: NCT00259324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity
Description: Diet and Activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity
Description: Diet and Activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet and Activity
Description: Diet and Activity
Study: NCT00284089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
Study: NCT01314105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Study: NCT02935582

Intervention type: DRUG
Intervention: Enstilar® aerosol foam
Description: Treatment according to local labelling

Intervention type: DRUG
Intervention: Other topical
Description: Treatment according to local practise
Study: NCT01925157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3090106 - SQ
Description: Administered SQ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3090106 - SQ
Description: Administered SQ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3090106 - IV
Description: Administered IV.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SQ
Description: Administered SQ.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SQ
Description: Administered SQ.
Study: NCT02858180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
Description: 1 pill once daily of SOF/LDV FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
Description: 1 pill once daily of SOF/LDV FDC
Study: NCT01139099

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Psychotherapy
Description: integrated group psychotherapy, including the interpersonal and cognitive group therapy
Study: NCT02061449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal lesional radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal lesional radiation
Study: NCT03251794

Intervention type: DIAGNOSTIC_TEST
Intervention: three dimensional ultrasound
Description: evaluation of the suprarenal glands

Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler
Description: Doppler evaluation of the suprarenal artery
Study: NCT03066219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421
Description: A topical solution of BRIM421 ophthalmic drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle ophthalmic drops